Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor

Asthma: two-thirds of patients suffer persistently

Published By Datamonitor

AstraZeneca/Targacept: another nail in the coffin for TC-5214

New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.

Published By Datamonitor

AstraZeneca: Crestor experiences additional setbacks

Withdrawal from the European approval process by three member states represents additional obstacles for Crestor, heightens concerns over safety, and will undoubtedly slow revenue gains for AstraZeneca. Therefore, although forecast to achieve blockbuster sales of $3.8 billion in 2010, Crestor will fail to make as significant an impact on the anti-dyslipidemic market as Lipitor did upon launch.

Published By Datamonitor

Breast cancer: 463,000 new cases predicted in 2010

Published By Datamonitor

Cancer therapies: cytotoxics rise and fall

Published By Datamonitor

Cancer: breast tumors most prevalent in 2001

Published By Datamonitor

Cancer: launch of angiogenesis inhibitors will increase treatment options

Published By Datamonitor

Cardiac surgery: UK PCI procedures to rise 5.4%

Published By Datamonitor

Cardiovascular advertising: dyslipidemia is 97% of spend

Published By Datamonitor